Tag Archive | "oncology"

iTeos Therapeutics signs pharma licensing deal with Pfizer

Tags: , , ,


iTeos Therapeutics in a pharma licensing deal with Pfizer will license the rights to three of its anti-tumor compounds for $24 million, as it attempts to get the backing of a global pharmaceutical firm for the development and commercialization of its IDO1 and TDO2 drug candidates. Read the full story

Chugai Pharmaceutical Ltd – Japan’s number one biopharmaceutical company

Tags: , ,


Chugai Pharmaceutical manufactures, sells, imports and exports pharmaceuticals and has become the leading biopharmaceutical company in Japan. Read the full story

Pharmacyclics: Partnering activity 2009-2014

Tags: ,


Pharmacyclics, listed as a new big biotech entrant in 2014, works to improve the lives of cancer affected patients by entering into strategic partnering deals to support its product pipeline. Read the full story

Aduro signs a pharma deal worth $847 million with Janssen

Tags: , , ,


Aduro Biotech just inked a pharma deal with the Johnson & Johnson Innovation Center in California to help it develop its nascent lung cancer therapies. Read the full story

Personalized Medicine in Oncology Partnering Terms and Agreements

Tags: , , ,


The Personalized Medicine in Oncology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the personalized medicine in oncology partnering agreements entered into by the worlds leading healthcare companies. Read the full story

Cancer Diagnostics Partnering Terms and Agreements

Tags: , ,


The Cancer Diagnostics Partnering Agreements report provides an understanding and access to the cancer diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

 

  • Trends in cancer diagnostics partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Cancer diagnostics partnering contract documents
  • Top cancer diagnostics deals by value

 

The Cancer Diagnostics Partnering Agreements report provides an understanding and access to the cancer diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

 

The report provides an understanding and analysis of how and why companies enter cancer diagnostics partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors diagnostics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes companion, imaging, CT, MRI, ultrasound, in vitro, molecular, prognostics and theranostics diagnostics deals and alliances.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

 

This report contains over 900 links to online copies of actual cancer diagnostics deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of cancer diagnostics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in cancer diagnostics dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

 

Chapter 3 provides a review of the leading cancer diagnostics deals since 2009. Deals are listed by headline value and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of cancer diagnostics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 5 provides a comprehensive and detailed review of cancer diagnostics partnering deals signed and announced since January 2009, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc). Each deal title links via Weblink to an online version of the deal record providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive and detailed review of cancer diagnostics deals with a specific focus on oncology therapy area for deals since 2009. Each deal title links via Weblink to an online version of the deal record and where available links to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 7 provides a comprehensive and detailed review of cancer diagnostics deals with a specific focus on diagnostics technology area for deals since 2009. Each deal title links via Weblink to an online version of the deal record and where available links to an online version of the actual contract document, providing easy access to each contract document on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in cancer diagnostics partnering and dealmaking since 2009.

 

In addition, a comprehensive appendix is provided organized by cancer diagnostics partnering company A-Z , deal type definitions and cancer diagnostics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of cancer diagnostics technologies and products.

 

Report scope

 

Cancer Diagnostics Partnering Agreements is intended to provide the reader with an in-depth understanding and access to cancer monoclonal antibody trends and structure of deals entered into by leading companies worldwide.

 

Cancer Diagnostics Partnering Agreements includes:

 

  • Trends in cancer diagnostics dealmaking in the biopharma industry since 2009
  • Analysis of cancer diagnostics deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to over 900 cancer diagnostics deal records
  • The leading cancer diagnostics deals by value since 2009
  • Includes companion, imaging, CT, MRI, ultrasound, in vitro, molecular, prognostics and theranostics diagnostics deals and alliances since 2007

 

In Cancer Diagnostics Partnering Agreements, the available deals are listed by:

 

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific oncology therapy target
  • DIagnostics type

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The Cancer  Diagnostics Agreements report provides comprehensive access to available deals and contract documents for over 900 cancer diagnostics deals. Analyzing actual contract agreements allows assessment of the following:

 

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Read the full story

Pharmacyclics: The talk of the partnering town

Tags: ,


Pharmacyclics is a biopharmaceutical company founded in April 1991 discovering and developing medications to treat and alleviate the suffering of oncology patients. Read the full story

Pfizer and Kyowa Hakko Kirin start a pharma alliance for immuno-oncology study

Tags: , , ,


Pfizer and Kyowa Hakko Kirin have entered into an pharma alliance agreement to explore the therapeutic potential of the combination of Pfizer’s PF-05082566 with Kyowa Hakko Kirin’s anti-CCR4 antibody mogamulizumab. Read the full story

Genmab: Partnering activity 2009-2014

Tags: , ,


Genmab, a top big biotech company, headquartered in Denmark is one of the leaders today in the human antibody therapeutics market for cancer treatment. Read the full story

Genmab: Rapidly progressing in the field of antibodies

Tags: , ,


Genmab is an internationally recognised biotechnology company developing human antibody therapeutics primarily for cancer. Read the full story